Medical Care

Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Research Report 2025

This report aims to provide a comprehensive presentation of the global market for Non-Peptide Drugs of Angiotensin II Receptor Antagonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Peptide Drugs of Angiotensin II Receptor Antagonist.
The Non-Peptide Drugs of Angiotensin II Receptor Antagonist market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Peptide Drugs of Angiotensin II Receptor Antagonist companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Merck
AstraZeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals 
Sun Pharmaceutical
Mylan
Alembic Pharmaceuticals
Lupin
Aurobindo Pharma
Amneal Pharmaceuticals
Boehringer Ingelheim
Segment by Type
Valsartan
Irbesartan
Candesartan Cilexetil
Eprosartan
Irbesartan
Telmisartan
losartan
Olmesartan Medoxomil
Allisartan isoproxil
Segment by Application
High Blood Pressure
Congestive Heart Failure
Left Ventricular Hypertrophy
Atherosclerosis
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Peptide Drugs of Angiotensin II Receptor Antagonist company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Valsartan
1.2.3 Irbesartan
1.2.4 Candesartan Cilexetil
1.2.5 Eprosartan
1.2.6 Irbesartan
1.2.7 Telmisartan
1.2.8 losartan
1.2.9 Olmesartan Medoxomil
1.2.10 Allisartan isoproxil
1.3 Market by Application
1.3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 High Blood Pressure
1.3.3 Congestive Heart Failure
1.3.4 Left Ventricular Hypertrophy
1.3.5 Atherosclerosis
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Perspective (2020-2031)
2.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Region
2.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Region (2020-2025)
2.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Region (2026-2031)
2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Dynamics
2.3.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Trends
2.3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
2.3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
2.3.4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue
3.1.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue (2020-2025)
3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Players (2020-2025)
3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
3.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio
3.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2024
3.5 Global Key Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist Head office and Area Served
3.6 Global Key Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist, Product and Application
3.7 Global Key Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Breakdown Data by Type
4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Type (2020-2025)
4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2026-2031)
5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Breakdown Data by Application
5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Application (2020-2025)
5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2020-2031)
6.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025)
6.4 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2020-2031)
7.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025)
7.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2020-2031)
8.2 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2020-2031)
9.2 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025)
9.4 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2020-2031)
10.2 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.3.5 Merck Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.4.5 AstraZeneca Recent Development
11.5 Jhonson and Johnson
11.5.1 Jhonson and Johnson Company Details
11.5.2 Jhonson and Johnson Business Overview
11.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.5.5 Jhonson and Johnson Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.6.5 Eli Lilly Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.7.5 Sanofi Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Bayer Business Overview
11.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.9.5 Bayer Recent Development
11.10 GSK
11.10.1 GSK Company Details
11.10.2 GSK Business Overview
11.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.10.5 GSK Recent Development
11.11 Teva Pharmaceutical
11.11.1 Teva Pharmaceutical Company Details
11.11.2 Teva Pharmaceutical Business Overview
11.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.11.4 Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.11.5 Teva Pharmaceutical Recent Development
11.12 Shenzhen Salubris Pharmaceuticals 
11.12.1 Shenzhen Salubris Pharmaceuticals  Company Details
11.12.2 Shenzhen Salubris Pharmaceuticals  Business Overview
11.12.3 Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.12.4 Shenzhen Salubris Pharmaceuticals  Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.12.5 Shenzhen Salubris Pharmaceuticals  Recent Development
11.13 Sun Pharmaceutical
11.13.1 Sun Pharmaceutical Company Details
11.13.2 Sun Pharmaceutical Business Overview
11.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.13.4 Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.13.5 Sun Pharmaceutical Recent Development
11.14 Mylan
11.14.1 Mylan Company Details
11.14.2 Mylan Business Overview
11.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.14.4 Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.14.5 Mylan Recent Development
11.15 Alembic Pharmaceuticals
11.15.1 Alembic Pharmaceuticals Company Details
11.15.2 Alembic Pharmaceuticals Business Overview
11.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.15.4 Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.15.5 Alembic Pharmaceuticals Recent Development
11.16 Lupin
11.16.1 Lupin Company Details
11.16.2 Lupin Business Overview
11.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.16.4 Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.16.5 Lupin Recent Development
11.17 Aurobindo Pharma
11.17.1 Aurobindo Pharma Company Details
11.17.2 Aurobindo Pharma Business Overview
11.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.17.4 Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.17.5 Aurobindo Pharma Recent Development
11.18 Amneal Pharmaceuticals
11.18.1 Amneal Pharmaceuticals Company Details
11.18.2 Amneal Pharmaceuticals Business Overview
11.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.18.4 Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.18.5 Amneal Pharmaceuticals Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Details
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
11.19.5 Boehringer Ingelheim Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Valsartan
Table 3. Key Players of Irbesartan
Table 4. Key Players of Candesartan Cilexetil
Table 5. Key Players of Eprosartan
Table 6. Key Players of Irbesartan
Table 7. Key Players of Telmisartan
Table 8. Key Players of losartan
Table 9. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2020-2025)
Table 13. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2026-2031)
Table 15. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Trends
Table 16. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
Table 17. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
Table 18. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
Table 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players (2020-2025)
Table 21. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2024)
Table 22. Ranking of Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist, Headquarters and Area Served
Table 25. Global Key Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist, Product and Application
Table 26. Global Key Players of Non-Peptide Drugs of Angiotensin II Receptor Antagonist, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2020-2025)
Table 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2026-2031)
Table 32. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2020-2025)
Table 34. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2026-2031)
Table 36. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2026-2031) & (US$ Million)
Table 51. Pfizer Company Details
Table 52. Pfizer Business Overview
Table 53. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 54. Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. Novartis Company Details
Table 57. Novartis Business Overview
Table 58. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 59. Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. Merck Company Details
Table 62. Merck Business Overview
Table 63. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 64. Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 65. Merck Recent Development
Table 66. AstraZeneca Company Details
Table 67. AstraZeneca Business Overview
Table 68. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 69. AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 70. AstraZeneca Recent Development
Table 71. Jhonson and Johnson Company Details
Table 72. Jhonson and Johnson Business Overview
Table 73. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 74. Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 75. Jhonson and Johnson Recent Development
Table 76. Eli Lilly Company Details
Table 77. Eli Lilly Business Overview
Table 78. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 79. Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 80. Eli Lilly Recent Development
Table 81. Sanofi Company Details
Table 82. Sanofi Business Overview
Table 83. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 84. Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 85. Sanofi Recent Development
Table 86. Bristol-Myers Squibb Company Details
Table 87. Bristol-Myers Squibb Business Overview
Table 88. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 89. Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 90. Bristol-Myers Squibb Recent Development
Table 91. Bayer Company Details
Table 92. Bayer Business Overview
Table 93. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 94. Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 95. Bayer Recent Development
Table 96. GSK Company Details
Table 97. GSK Business Overview
Table 98. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 99. GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 100. GSK Recent Development
Table 101. Teva Pharmaceutical Company Details
Table 102. Teva Pharmaceutical Business Overview
Table 103. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 104. Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 105. Teva Pharmaceutical Recent Development
Table 106. Shenzhen Salubris Pharmaceuticals  Company Details
Table 107. Shenzhen Salubris Pharmaceuticals  Business Overview
Table 108. Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 109. Shenzhen Salubris Pharmaceuticals  Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 110. Shenzhen Salubris Pharmaceuticals  Recent Development
Table 111. Sun Pharmaceutical Company Details
Table 112. Sun Pharmaceutical Business Overview
Table 113. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 114. Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 115. Sun Pharmaceutical Recent Development
Table 116. Mylan Company Details
Table 117. Mylan Business Overview
Table 118. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 119. Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 120. Mylan Recent Development
Table 121. Alembic Pharmaceuticals Company Details
Table 122. Alembic Pharmaceuticals Business Overview
Table 123. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 124. Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 125. Alembic Pharmaceuticals Recent Development
Table 126. Lupin Company Details
Table 127. Lupin Business Overview
Table 128. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 129. Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 130. Lupin Recent Development
Table 131. Aurobindo Pharma Company Details
Table 132. Aurobindo Pharma Business Overview
Table 133. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 134. Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 135. Aurobindo Pharma Recent Development
Table 136. Amneal Pharmaceuticals Company Details
Table 137. Amneal Pharmaceuticals Business Overview
Table 138. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 139. Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 140. Amneal Pharmaceuticals Recent Development
Table 141. Boehringer Ingelheim Company Details
Table 142. Boehringer Ingelheim Business Overview
Table 143. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
Table 144. Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025) & (US$ Million)
Table 145. Boehringer Ingelheim Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
Table 149. Authors List of This Report


List of Figures
Figure 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Picture
Figure 2. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type: 2024 VS 2031
Figure 4. Valsartan Features
Figure 5. Irbesartan Features
Figure 6. Candesartan Cilexetil Features
Figure 7. Eprosartan Features
Figure 8. Irbesartan Features
Figure 9. Telmisartan Features
Figure 10. losartan Features
Figure 11. Olmesartan Medoxomil Features
Figure 12. Allisartan isoproxil Features
Figure 13. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2024 VS 2031
Figure 15. High Blood Pressure Case Studies
Figure 16. Congestive Heart Failure Case Studies
Figure 17. Left Ventricular Hypertrophy Case Studies
Figure 18. Atherosclerosis Case Studies
Figure 19. Others Case Studies
Figure 20. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Report Years Considered
Figure 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region: 2024 VS 2031
Figure 24. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players in 2024
Figure 25. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2024)
Figure 26. The Top 10 and 5 Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2024
Figure 27. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2020-2031)
Figure 29. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2020-2031)
Figure 33. Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. U.K. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Nordic Countries Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2020-2031)
Figure 41. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Australia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2020-2031)
Figure 49. Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Country (2020-2031)
Figure 53. Turkey Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Pfizer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 58. Merck Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 59. AstraZeneca Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 60. Jhonson and Johnson Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 61. Eli Lilly Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 62. Sanofi Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 64. Bayer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 65. GSK Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 66. Teva Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 67. Shenzhen Salubris Pharmaceuticals  Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 68. Sun Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 69. Mylan Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 70. Alembic Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 71. Lupin Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 72. Aurobindo Pharma Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 73. Amneal Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 74. Boehringer Ingelheim Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2020-2025)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies